Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer

Shots:

• The companies will jointly develop vaccine candidates using Leidos’ PD-1 checkpoint inhibitors combined with GeoVax’s MVA-VLP vaccine platform
• GeoVax will design, construct, and characterize the developed product and further analysis will be done by Leidos
• GeoVax’s Modified Vaccinia Ankara (MVA) platform is used for developing in-vivo vaccines in the form of multimeric proteins or non-infectious VLPs (Virus-Like Particle)

Click here to read full press release/ article | Ref: GeoVax | Image: Axios